文献速递病毒性肝炎医院感染防控

冈比亚孕妇高病毒载量HBcrAg快速诊断试验现场性能与可接受性

Field Performance and Acceptability of the Hepatitis B Core-Related Antigen Rapid Diagnostic Test for Detecting High Viral Load Among Pregnant Women in The Gambia (PROTECT-B).
PubMed 文献 · Clin Infect Dis · 2026-01-01

血浆和毛细血管全血灵敏度分别为89.5%和88.2%,特异度分别为98.5%和98.7%。HBcrAg-RDT引导策略可识别全部符合治疗条件者,并将不必要治疗从100%降至4.1%。

要点

  • HBcrAg-RDT检测孕妇高病毒载量具高灵敏度和特异度。
  • HBcrAg-RDT引导策略可减少不必要的替诺福韦治疗。
  • 使用者对RDT易用性评价高,但孵育时间增加工作量。

核心结论

  • HBcrAg-RDT能准确识别需要抗病毒预防的孕妇,且被使用者接受。
  • 相比普遍预防策略,HBcrAg-RDT引导策略可减少不必要的替诺福韦使用。

研究设计与样本

  • 多中心前瞻性横断面研究,在冈比亚4个产前服务点纳入343例未治疗、HBsAg阳性孕妇。

主要发现

  • 343例中5.5%具有高病毒载量。
  • 血浆样本灵敏度89.5%(95%CI 66.9-98.7),特异度98.5%(96.4-99.5)。
  • 毛细血管全血灵敏度88.2%(63.6-98.5),特异度98.7%(96.6-99.6)。
  • HBcrAg-RDT引导策略可识别全部4例符合条件者,将不必要治疗从100%(73/73)降至4.1%(3/73)。

临床怎么用

  • 在资源有限地区,HBcrAg-RDT可作为HBV DNA检测的即时替代方法,用于筛选需抗病毒预防的孕妇。
  • 采用HBcrAg-RDT引导策略可避免普遍预防带来的不必要替诺福韦暴露。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mother-to-child transmission (MTCT) remains a major source of chronic hepatitis B virus (HBV) infection globally. Identifying pregnant women eligible for antiviral prophylaxis requires HBV DNA testing, which is often inaccessible in resource-limited settings. The hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) may offer a point-of-care alternative, yet prospective evaluation in antenatal care is lacking. We assessed its diagnostic performance, clinical impact, and user acceptability within a MTCT triple elimination program. METHODS: In this multicenter prospective cross-sectional study, treatment-naive, hepatitis B surface antigen (HBsAg)-positive pregnant women were enrolled across 4 antenatal services in The Gambia. HBcrAg-RDT diagnostic accuracy for detecting high viral load (≥200 000 IU/mL) was evaluated using plasma and capillary whole blood samples, with GeneXpert HBV viral load as the reference standard. RESULTS: Among 343 HBsAg-positive pregnant women, 5.5% had high viral load. The HBcrAg-RDT demonstrated sensitivities of 89.5% (95% CI 66.9-98.7) with plasma and 88.2% (63.6-98.5) with capillary blood, and specificities of 98.5% (96.4-99.5) and 98.7% (96.6-99.6), respectively. At 1 site implementing universal tenofovir prophylaxis, 77 women started treatment, of whom only 4 had HBV DNA ≥ 200 000 IU/mL. An HBcrAg-RDT-guided strategy would have identified all eligible women (4/4) while reducing unnecessary treatment from 100% (73/73) to 4.1% (3/73). Users rated RDT ease-of-use highly, although incubation time modestly increased workload. CONCLUSIONS: The HBcrAg-RDT accurately identified pregnant women requiring antiviral prophylaxis and was accepted by users. It represents a feasible, lower-cost alternative to HBV DNA testing and may reduce unnecessary tenofovir use compared with universal prophylaxis strategies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Famiglietti AM, Drammeh S, Vo-Quang E, et al. Field Performance and Acceptability of the Hepatitis B Core-Related Antigen Rapid Diagnostic Test for Detecting High Viral Load Among Pregnant Women in The Gambia (PROTECT-B). Clin Infect Dis. 2026. PMID: 42119150. doi:10.1093/cid/ciag311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。